Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is a medical device company with strong earnings, increased guidance, and a conservative outlook. Their success is attributed to strategic partnerships, expansion opportunities, and a capital-light business model. Although there are potential risks, the company is expected to continue its strong growth through innovative products and a focus on sustainable profitability. Their current price target may have been lowered, but there is still potential for upside given their projected growth and unique approach to sacropelvic anatomy.

Bears say

SI-BONE is a medical device company in the orthopedic and spinal industry with a narrower focus on sacroiliac joint dysfunction and fusion. Despite its success in building the SI joint fusion market and expanding its product line, the company faces risks including reimbursement challenges and competition from larger players. Additionally, its single anatomical focus and rapid sales force expansion could lead to commercial missteps and lack of profitability. These factors, along with a compressed peer sector valuation, justify a negative outlook on the stock.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.